Winrevair (sotatercept)
Q2 2026 sales $588M, up 75%; the fastest-growing large Merck drug.
The numbers
What it is
Sotatercept, a treatment for pulmonary arterial hypertension, marketed in the US and other markets. Its growth is one of the main offsets to Gardasil's decline.↗ source
Why it matters to the stock. Winrevair is the strongest non-Keytruda growth driver and a test of whether Merck can build a second large cardiopulmonary franchise.
News
FDA adds HYPERION data to Winrevair label for newly diagnosed pulmonary arterial hypertension
The FDA approved an updated Winrevair (sotatercept) label that adds Phase 3 HYPERION data for adults newly diagnosed with pulmonary arterial hypertension who are at intermediate to high risk of progression.
Merck Q2 2026 sales rise 5% to $16.6B; 2026 EPS guidance cut to $2.66-2.76 on acquisition charges
Merck reported second-quarter 2026 sales of $16.61 billion, up 5% (4% excluding FX), with Keytruda and Keytruda Qlex at $8.37 billion.
Merck Q1 2026 sales rise 5% to $16.3B; non-GAAP loss of $1.28 per share after Cidara charge; guidance raised
Merck reported first-quarter 2026 sales of $16.3 billion, up 5% (3% excluding currency), with Keytruda and Keytruda Qlex at $8.0 billion, up 12%.